Literature DB >> 3886134

Quantitative enzyme-linked immunosorbent assay for the estrogen-regulated Mr 24,000 protein in human breast tumors: correlation with estrogen and progesterone receptors.

D J Adams, W L McGuire.   

Abstract

A competitive enzyme-linked immunoassay has been developed to quantitate the Mr 24,000 estrogen-regulated protein (p24) in human breast tumors and tumor cell lines. The concentration of monoclonal antibody used to coat polystyrene microtiter assay plates was critical in optimizing assay sensitivity versus precision and demonstrated marked differences between plate types. Analysis of 114 human breast tumor cytosols revealed a 4-log range in p24 concentration with a median value of 1 microgram/mg cytosol protein. The abundance of p24 in breast tumors in vivo is therefore similar to that observed previously in hormone-responsive breast tumor cells in vitro. Elevated expression of p24 in these specimens was found to correlate well with presence of estrogen and progesterone receptors (P = 0.0002 by Pearson chi 2 analysis) with the correlation coming primarily through estrogen receptor. This result was confirmed by immunoblot analysis of p24 in 76 additional tumor cytosols and suggests that p24 may be a valuable marker for differentiation in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886134

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Immunological evidence for the identity between the hsp27 estrogen-regulated heat shock protein and the p29 estrogen receptor-associated protein in breast and endometrial cancer.

Authors:  D R Ciocca; E H Luque
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

2.  Specific polypeptide differences in normal versus malignant human breast tissues by two-dimensional electrophoresis.

Authors:  P J Wirth; V Egilsson; V Gudnason; S Ingvarsson; S S Thorgeirsson
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

3.  Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue.

Authors:  D R Ciocca; A O Stati; M M Amprino de Castro
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

4.  Small heat-shock protein is expressed in meningiomas and in granulofilamentous inclusion bodies.

Authors:  N Yokoyama; T Iwaki; J E Goldman; J Tateishi; M Fukui
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

5.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Overexpression of 27-kDa heat-shock protein in MCF-7 breast cancer cells: effects on lymphocyte-mediated killing by natural killer and gamma delta T cells.

Authors:  D M Mahvi; S W Carper; F K Storm; S R Teal; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

7.  Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study.

Authors:  B Têtu; J Brisson; J Landry; J Huot
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

8.  A cDNA for the estradiol-regulated 24K protein: control of mRNA levels in MCF-7 cells.

Authors:  I Moretti-Rojas; S A Fuqua; R A Montgomery; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

9.  A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer.

Authors:  S Love; R J King
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

10.  Detection of P24 protein in human breast cancer: influence of receptor status and oestrogen exposure.

Authors:  L Seymour; W R Bezwoda; K Meyer; C Behr
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.